Stewart Lyman

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.

Recent posts and comments

• “Don’t Touch My Bags If You Please, Mr. Customs Man”

  Imagine the following scenario for a minute: A middle-aged man books a round trip ticket from San Francisco to Shanghai. His reservation indicates this will be a short trip; he is... Read more »

• Why Big Pharma Wants To Be Like Big Biotech

  Why would a Big Pharma company want to remake itself as a biotech? In a recent Xconomy piece, I discussed the changes in Roche’s corporate culture brought on by their recent... Read more »

• Forget the Shortcuts: Creating a Truly Innovative Biotech Culture

  Watching the acquisition of Genentech by Roche has been a fascinating process. I wasn’t so interested in the eventual price paid per share, but whether Basel, Switzerland-based Roche, one of the... Read more »

• Measuring Success in the Biotech World

  What defines success in biotechnology? I’ve noticed that many companies are described as being successful, but there’s no widely agreed upon definition for success within the industry. Lack of agreement on... Read more »

• Two Simple Ways to Revitalize Seattle Biotech

  Seattle’s biotech community used to be among the top-ranked in the nation. But as some 2,500 layoffs have piled up in the local biotech sector since 2002, Seattle has tumbled in... Read more »